Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 6:25 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 6,312 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Advanced therapy Clear all

Conditions: Esophageal Achalasia, Esophageal Spasm, Diffuse, Esophageal Motility Disorders
Interventions: peroral endoscopic myotomy, Botulinum toxin injection; Procedure
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Advanced Solid Neoplasm
Interventions: Pevonedistat, Docetaxel, Carboplatin, Paclitaxel; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 8
States / cities: Santa Monica, California • Tampa, Florida • Detroit, Michigan + 5 more

Conditions: Advanced Cancer
Interventions: Interactive Music Therapy, Verbal support; Behavioral
Lead sponsor: Drexel University; Other
Eligibility: 18 Years and older
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 3
States / cities: Philadelphia, Pennsylvania

Conditions: Lymphoma, Malignant, Advanced Solid Neoplasms
Interventions: TAK-659; Drug
Lead sponsor: Calithera Biosciences, Inc; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 3
States / cities: New Haven, Connecticut • Detroit, Michigan • The Bronx, New York

Conditions: Adult Solid Tumor
Interventions: SQZ-eAPC-HPV, Pembrolizumab; Biological
Lead sponsor: SQZ Biotechnologies; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 9
States / cities: Scottsdale, Arizona • Duarte, California • Aurora, Colorado + 5 more

Conditions: Prostate Cancer
Interventions: ARN-509 (Phase 1), ARN-509 (Phase 2); Drug
Lead sponsor: Aragon Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2025
U.S. locations: 15
States / cities: San Diego, California • San Francisco, California • Atlanta, Georgia + 12 more

Conditions: Chronic Kidney Disease
Interventions: Pharmacist based QI program, Usual Care; Other
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 85 Years
Enrollment: 2,199 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Breast Cancer
Interventions: Lapatinib, Trastuzumab, Endocrine; Drug
Lead sponsor: Baylor Breast Care Center; Other
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 6
States / cities: Birmingham, Alabama • Chicago, Illinois • Baltimore, Maryland + 3 more

Conditions: Recurrent Non-Small Cell Lung Carcinoma, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-Small Cell Lung Cancer
Interventions: Azacitidine, Docetaxel, Entinostat, Gemcitabine Hydrochloride, Irinotecan Hydrochloride, Laboratory Biomarker Analysis, Pemetrexed Disodium; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 5
States / cities: Los Angeles, California • Newport Beach, California • Baltimore, Maryland + 1 more

Conditions: Non-small Cell Lung Cancer, Postmenopausal Women
Interventions: fulvestrant (Faslodex), anastrozole (Arimidex), Bevacizumab (Avastin), Best supportive care; Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older · Female only
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Neoplasms, Metastatic Cancer, Advanced Cancer, Solid Tumor, Non Small Cell Lung Cancer Metastatic, Non Small Cell Lung Cancer Stage IIIB, Non Small Cell Lung Cancer
Interventions: Niraparib, TSR-042, Carboplatin-Paclitaxel, Bevacizumab, TSR-022, Carboplatin-Pemetrexed, Carboplatin-Nab-Paclitaxel; Drug
Lead sponsor: Tesaro, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 8
States / cities: Scottsdale, Arizona • Encinitas, California • San Marcos, California + 5 more

Conditions: Thymoma, Thymus Neoplasms
Interventions: Sunitinib; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 100 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2024
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hereditary Thyroid Gland Medullary Carcinoma, Locally Advanced Thyroid Gland Medullary Carcinoma, Multiple Endocrine Neoplasia Type 2A, Multiple Endocrine Neoplasia Type 2B, Recurrent Thyroid Gland Medullary Carcinoma, Sporadic Thyroid Gland Medullary Carcinoma, Stage III Thyroid Gland Medullary Carcinoma AJCC v7, Stage IV Thyroid Gland Medullary Carcinoma AJCC v7, Stage IVA Thyroid Gland Medullary Carcinoma AJCC v7, Stage IVB Thyroid Gland Medullary Carcinoma AJCC v7, Stage IVC Thyroid Gland Medullary Carcinoma AJCC v7
Interventions: Sorafenib Tosylate; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2022
U.S. locations: 3
States / cities: St Louis, Missouri • Durham, North Carolina • Columbus, Ohio

Conditions: Advanced Or Metastatic Merkel Cell Carcinoma
Interventions: IFx-Hu2.0, Pembrolizumab; Drug
Lead sponsor: TuHURA Biosciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: Tampa, Florida • Madison, Wisconsin

Conditions: Solid Tumor, Pancreatic Neuroendocrine Tumor, Neuroendocrine Tumors
Interventions: PAC-1; Drug
Lead sponsor: Vanquish Oncology, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 3
States / cities: Chicago, Illinois • Baltimore, Maryland • Saint Paul, Minnesota

Conditions: Primary Orthostatic Tremor
Interventions: Magstim RapidStim2, Sham Magstim RapidStim2, Fullerton Advanced Balance (FAB) Scale, Timed "Up & Go" Test (TUG) test, 10m walk test, Tremor electrophysiology, Cerebellar-brain Inhibition (CBI); Device · Other
Lead sponsor: University of Florida; Other
Eligibility: 30 Years to 75 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Coronary Artery Disease
Interventions: Not listed
Lead sponsor: University of California, San Francisco; Other
Eligibility: 21 Years and older
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2022
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Bone Sarcomas
Interventions: Zanzalintinib; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: recombinant interleukin-12, aldesleukin, laboratory biomarker analysis; Biological · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Cutaneous Metastases
Interventions: Diphencyprone (DPCP); Drug
Lead sponsor: Nicholas Gulati; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2030
U.S. locations: 1
States / cities: New York, New York

Conditions: Melanoma Stage IV, Solid Tumor
Interventions: GIM-531, Anti-PD-1 monoclonal antibody; Drug
Lead sponsor: Georgiamune Inc; Industry
Eligibility: 18 Years and older
Enrollment: 117 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 11
States / cities: Scottsdale, Arizona • Bakersfield, California • Fullerton, California + 8 more

Conditions: Head and Neck Cancer
Interventions: cisplatin, vandetanib, radiation therapy; Drug · Radiation
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 63
States / cities: Scottsdale, Arizona • Duarte, California • La Jolla, California + 52 more

Conditions: Sarcoma, Ewing, Sarcoma
Interventions: Combination metyrosine-derivative, low-dose methoxsalen, phenytoin and sirolimus (MPS); Drug
Lead sponsor: Sarcoma Oncology Research Center, LLC; Other
Eligibility: 12 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 1
States / cities: Santa Monica, California

Conditions: Melanoma
Interventions: cyclophosphamide, Mature dendritic cell vaccine; Drug · Biological
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2016
U.S. locations: 1
States / cities: St Louis, Missouri

Search by objective public record fields.

Peroral Endoscopic Myotomy Versus Botulinum Toxin Injection in Spastic Esophageal Disorders

A Study to Evaluate the Effects of Pevonedistat on the Corrected QT (QTc) Interval in Participants With Advanced Solid Tumors

Pain Management Support Study for Patients With Advanced Cancer

A Study to Evaluate the Effect of Food on the Pharmacokinetics (PK) of TAK-659 in Participants With Advanced Solid Tumor

Study of SQZ-eAPC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors

Safety, Pharmacokinetic and Proof-of-Concept Study of ARN-509 (Apalutamide) in Castration-Resistant Prostate Cancer (CRPC)

A Chronic Care Model Based Quality Improvement (QI) Program to Improve the Care of Patients With Chronic Kidney Disease (CKD)

Lapatinib and Trastuzumab With or Without Endocrine Therapy

Azacitidine and Entinostat Before Chemotherapy in Treating Patients With Advanced Non-small Cell Lung Cancer

Fulvestrant and Anastrozole as Consolidation Therapy in Postmenopausal Women With Advanced Non-small Cell Lung Cancer

Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042

Sunitinib for Advanced Thymus Cancer Following Earlier Treatment

Sorafenib Tosylate in Treating Patients With Metastatic, Locally Advanced, or Recurrent Medullary Thyroid Cancer

IFx-Hu2.0 As An Adjunctive Therapy To Pembrolizumab In Advanced Or Metastatic Merkel Cell Carcinoma (MCC)

Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 1

rTMS Therapy for Primary Orthostatic Tremor

Dynamic Cardiac SPECT Imaging

A Phase 2 Trial of Zanzalintinib in Advanced/Metastatic Bone Sarcomas (ZAMBONE)

Interleukin-12 Plus Interleukin-2 in Treating Patients With Advanced Solid Tumors

Diphencyprone Plus Immune Checkpoint Inhibition in the Treatment of Cutaneous Metastases

Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors

Chemotherapy and Radiation Therapy (RT) With or Without Vandetanib in Treating Patients With High-Risk Stage III or Stage IV Head and Neck Cancer

SM-88 Maintenance Therapy for Advanced Ewing's Sarcoma and as Salvage Therapy for Sarcoma

Dendritic Cells (White Blood Cells) Vaccination for Advanced Melanoma